Clinical trial · Interventional
Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency
Comparison of Secretin Enhanced MRCP to Endoscopic Pancreatic Function Testing in Diagnosing Exocrine Insufficiency in Patients Who Have Undergone Pancreas Cancer Resection
NCT01094600CI-TRIAL-00007311withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of our study is to evaluate S-MRCP, in comparison to direct pancreatic function, to measure pancreatic exocrine function in patients who have symptoms suspicious for insufficiency. We hypothesize that S-MRCP imaging parameters will correlate well with the direct pancreatic exocrine functioning.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Synthetic Human Secretin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Secretin
- description
- Single arm (open label).
- interventionNames
- Drug: Synthetic Human Secretin
Primary outcomes (1)
- measure
- Primary outcome: correlation between S-MRCP with ePFT
- timeFrame
- 30 days
- description
- The primary outcome that we will be measuring will be correlation between duodenal filling on S-MRCP (expressed as percent of duct volume change from baseline and maximal values following secretin administration) with maximal bicarbonate concentration from ePFT.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age and older * Tissue-confirmed diagnosis of pancreatic adenocarcinoma * Undergone surgical resection for adenocarcinoma no less than 3 months prior to enrollment * Report significant abdominal pain/bloating or steatorrhea \>3x/week or demonstrate weight loss corresponding to \>10% of pre-surgery BMI. * Scheduled for EGD/EUS to investigate the above clinical indicators. Exclusion Criteria: * History of any radiation therapy to the abdomen prior to surgery * Any contraindication to MRI, including but not limited to implanted metal devices (e.g. pacemaker, berry aneurysm clips, neural stimulator, cochlear implants, or metal in the eye) * Presence of pancreatic duct stent * Treatment with an investigational drug within 1 month prior to the day of the study drug administration * Current enrollment in any other interventional study * Creatinine greater than 2.0 * Significant liver disease, liver masses, or evidence of portal hypertension * Pregnancy * History of sensitivity to secretin * Unwilling or unable to sign informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.